WO2006073164A1 - 透析用製剤 - Google Patents
透析用製剤 Download PDFInfo
- Publication number
- WO2006073164A1 WO2006073164A1 PCT/JP2006/300051 JP2006300051W WO2006073164A1 WO 2006073164 A1 WO2006073164 A1 WO 2006073164A1 JP 2006300051 W JP2006300051 W JP 2006300051W WO 2006073164 A1 WO2006073164 A1 WO 2006073164A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- citrate
- concentration
- dialysis
- dialysate
- bicarbonate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1654—Dialysates therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Definitions
- the present invention relates to a bicarbonate dialysate used for hemodialysis, and in particular, acetic acid as a pH adjuster.
- Hemodialysis treatment is the most common blood purification therapy for patients with chronic renal failure (CRF).
- CRF chronic renal failure
- the purpose of the hemodialysis treatment is to correct the concentration of serum electrolyte components and the acid monobasic equilibrium, in addition to removing waste products from the blood and removing water by dialysis.
- the dialysate used for this purpose requires a large amount of alkalizing agent. This is mainly for correcting metabolic acidosis associated with CRF. Therefore, it is natural that bicarbonate is the most suitable as such an alkalinizing agent, and bicarbonate dialysate is used for hemodialysis therapy.
- bicarbonate dialysate the contained bicarbonate ions react with calcium ions and magnesium ions to produce insoluble compounds (compounds of metal carbonates such as calcium carbonate and magnesium carbonate).
- problems such as being unstable and difficult to preserve for a long time because bacteria are easy to propagate.
- bicarbonate dialysis In this bicarbonate dialysis, generally, an electrolyte component containing calcium ions, magnesium ions, etc., a pH adjuster and a so-called “agent A” containing Z or glucose, and bicarbonate to be a bicarbonate ion. It also has a sodium strength, so it consists of a so-called “B agent”. This is to prevent bicarbonate ions from reacting with calcium ions and magnesium ions to form insoluble compounds such as metal carbonates (calcium carbonate, magnesium carbonate, etc.).
- bicarbonate dialysis contains acetic acid, sodium acetate, etc. as pH adjusters, and its content is not as high as previous acetic acid dialysis, but the pH of the dialysate is reduced to 7-8. Prepare to contain about 6-12mEqZL of acetic acid!
- Non-Patent Document 1 the standard value of ionic calcium concentration in dialysis patients is 2. 05-2.60 mEq ZL (1.025-1.30 mmol ZL) (Non-Patent Document 1). It is important to ensure this value.
- the calcium level in normal human serum is 8.0 to: LO. 5 mgZdL, of which ionized calcium, that is, ionized calcium, must be greater than ImmoL ZL
- ionized calcium that is, ionized calcium
- Patent Document 1 Japanese Patent Application Laid-Open No. 2003-104869
- Non-Patent Document 1 "Testing and management of dialysis patients" author, edited by Fumitake Shimojo, p. 32, June 21, 1999 First edition, 1st edition (Chugai Medical Company)
- Non-Patent Document 2 Eiba Chiba et al., Dialysis Society, 21 (6): 517-522 (1988)
- Non-Patent Document 3 Fumiyoshi Nakayama et al., Artificial Organ, 18 (3): 1220-1224 (1989)
- the present invention provides a dialysis preparation containing acetic acid and Z or sodium acetate and containing ionic calcium in an acetic acid-free bicarbonate dialysis solution of ImmoLZL or higher. Is an issue.
- the pH adjuster is maintained while maintaining the optimum concentration of calcium as an electrolyte component to be added over an acetic acid-free bicarbonate dialysis solution.
- the concentration of ionic strength in the dialysate can be set to ImmoLZL or higher.
- the basic aspect of the present invention is that, in a bicarbonate dialysis solution using citrate and Z or citrate as a pH adjuster, the concentration of ionic calcium as an electrolyte component is ImmoLZL or more.
- the dialysate is characterized in that the contents of citrate and Z or citrate are adjusted so that
- the present invention relates to citrate and Z or sodium citrate as a pH adjuster, the citrate concentration in the dialysate is 1.5 mEqZL or less, and the sodium citrate concentration is 0.2. It is a dialysate characterized by adjusting the ionized calcium concentration to be lm moLZL or more by combining within the range of ⁇ 0.5 mEqZL.
- the present invention includes acetic acid and Z or acetate as a pH adjuster.
- concentration of calcium ion which is an electrolyte component, is adjusted to 1. OmmoLZL or higher with citrate and Z or citrate.
- the present invention is more specific in that citrate and Z or sodium citrate are used as pH adjusters, the citrate concentration in the dialysate is 1.5 mEq / L or less, and taenoic acid is used.
- This is a method of adjusting the concentration of ionic mineral to ImmoLZL or more by combining the sodium concentration within the range of 0.2 to 0.5 mEq / L.
- the present invention provides an electrolyte component for preparing a bicarbonate dialysis solution, dialysis solution containing citrate and Z or citrate as a pH adjuster, and Z or glucose.
- Dialysis characterized in that it is an agent A and is adjusted with citrate and Z or a citrate salt so that the concentration of ionized calcium as an electrolyte component in the bicarbonate dialysis solution after preparation is ImmoLZL or higher. It is A preparation for pharmaceuticals.
- the agent A for dialysis preparations of the present invention is to combine sodium citrate within the range of 0.2 to 0.5 mEqZL after setting the citrate concentration to 1.5 mEqZL or less. It is an A preparation for dialysis preparations that has been adjusted so that the ionic calcium concentration is higher than ImmoLZL.
- the present invention is characterized in that a bicarbonate dialysis solution is prepared and dialyzed so that the ionic calcium concentration becomes ImmoLZL or higher without using acetic acid and Z or acetate. This is a hemodialysis method.
- the bicarbonate dialysate provided by the present invention is adjusted so that the ionic calcium concentration in the dialysate is not less than lmmo LZL. Therefore, a good bicarbonate dialysis solution that does not impose a burden on Ca 'bone metabolism is provided.
- the A agent for bicarbonate dialysis preparation provided by the present invention is obtained by combining the contents of citrate and Z or sodium taenoate so that the ionic calcium concentration becomes ImmoLZL or higher after the dialysate is prepared.
- Regulated and stable heavy coal Has the advantage of being able to supply acid dialysis fluid!
- the bicarbonate dialysate provided by the present invention does not contain acetic acid and Z or sodium acetate as pH adjusters used in conventional bicarbonate dialysate, and is an acid that also exists in the living body.
- the first feature lies in the fact that some citrate and / or sodium citrate is used. Thereby, a so-called acetic acid-free bicarbonate dialysis solution is prepared.
- the concentration of ionic calcium is maintained while maintaining the optimum calcium concentration in the dialysate.
- the second feature is that it is set to ImmoL / L or more.
- the bicarbonate bicarbonate dialyzer consists of an electrolyte component, so-called “agent A” containing citrate and / or sodium taenate as a pH adjuster, and Z or glucose, and an alkalinizer. It is a dialysate obtained by diluting and mixing two so-called “B agents” that also have the ability of sodium bicarbonate to function as sodium bicarbonate.
- a component contained as a dialysate component can be appropriately selected and blended as desired.
- sodium hydrogen carbonate but also other dialysate components can be appropriately blended even in “B agent”.
- the "agent A” for dialysis in the present invention is a preparation for preparing a bicarbonate dialysate by diluting and mixing with a sodium hydrogen carbonate solution (so-called “agent B”). May be a liquid or a solid agent.
- each reacting component may be stored separately. It can.
- the bicarbonate dialysis solution provided by the present invention is such that the concentration of ionic calcium is not less than ImmoLZL while maintaining the optimum calcium concentration in the dialysis solution.
- the adjustment can be carried out by adjusting the amount of citrate and / or sodium citrate added as a pH adjuster.
- the adjustment is performed by setting the citrate concentration in the dialysate to 1.5 mEq / L or less and combining the sodium citrate concentration within the range of 0.2 to 0.5 mEqZL.
- the ionic calcium concentration can be adjusted to ImmoLZL or higher.
- the pH is adjusted to be within the range of 7 to 8, and the pH adjusting agent is contained depending on the amount of the alkalizing agent usually contained. The amount is different and cannot be limited in general.
- the content of citrate and Z or sodium citrate is adjusted within the target pH range, and the ionized calcium concentration is adjusted to lm moLZL or higher. It has been found.
- dialysis agent A provided by the present invention is usually electrolyte component, also P H modifiers and Z contains glucose, as the force Cal electrolyte components, Kuen salts such as sodium Kuen acid
- Kuen salts such as sodium Kuen acid
- sodium chloride sodium, potassium salt potassium, magnesium chloride, calcium chloride salt, sodium lactate, potassium lactate, calcium lactate and the like are used.
- Preferable electrolyte compositions are sodium chloride sodium, potassium salt potassium, calcium salt calcium, and magnesium chloride.
- the blending amount of each component of the dialysate is preferably the following concentration as a bicarbonate dialysate when diluted and mixed to an appropriate concentration.
- citrate and Z or sodium citrate are used as pH adjusters. use.
- the amount of this citrate and Z or sodium citrate is determined when the bicarbonate dialysis solution is prepared, that is, when ⁇ agent A '' and ⁇ agent B '' are mixed and diluted appropriately.
- the amount can be adjusted to about 7-8, and the chelate with ionized calcium should be kept to a minimum, and the amount adjusted to ImmoLZL or higher should be included.
- the conventional bicarbonate dialysate contained acetic acid and Z or sodium acetate as a pH adjuster in "agent A”, whereas in the present invention, citrate and Z or sodium taenoate. And does not contain any acetic acid. Therefore, since only sodium bicarbonate can be used as an alkalizing agent, it has the advantage of being a more physiological formulation.
- citrate and Z or sodium citrate can be expected to suppress precipitation.
- two agents the so-called “agent A” containing electrolyte components, pH adjusting agents and Z or glucose, and “agent B”, which is the sodium bicarbonate power of bicarbonate ions, are composed of calcium ions and magnesium ions.
- agent A containing electrolyte components
- agent B which is the sodium bicarbonate power of bicarbonate ions
- a preparation for dialysis containing electrolyte components for preparing bicarbonate dialysate, citrate and sodium taenate as pH adjusting agents, and glucose was prepared in the following five formulations. That is, as electrolyte components, salt ⁇ sodium (NaCl) 214.8 g, salt ⁇ potassium (KC1) 5. 222g, calcium chloride (CaCl ⁇ 2 ⁇ 0) 7. 72g, magnesium chloride (MgCl ⁇ 6 ⁇ )
- citrate and sodium citrate as pH adjusters are contents adjusted so that the concentration becomes each concentration after the mixture dilution with B agent described later.
- Test 1 Ionic calcium concentration and pH value of dialysate in dialysate prepared using dialysate device
- AK-Solita registered trademark
- AK-Sorita registered trademark
- ⁇ FL solution
- Test 2 Ionic calcium concentration and pH value of dialysate in dialysate prepared using experimental glassware
- Dialysate prepared using laboratory glassware, and dialysate preparation for testing The production was performed as follows. That is, the amount of the above-mentioned B agent stock solution is accurately placed in a 350 mL volumetric flask in the amount shown in Table 2 below, 300 mL of water is added, and the A agent of each of the above treatments (formulations 1 to 5) is further added thereto. 10mL was added, and it was exactly 350mL with water to prepare a dialysate. In the same manner as in Test 1 above, dialysate was similarly prepared and tested for AK-Solita (registered trademark) 'DL (solution) and AK-Solita (registered trademark)' FL (solution).
- Table 3 shows the results for dialysate prepared using a personal dialyzer
- Table 4 shows the results for dialysate prepared using experimental glassware.
- the calcium concentration in the dialysate is fixed to a widely used constant concentration (3. OmEqZL), and the concentration of citrate as a pH adjuster at that time is fixed. It is understood that the ionized calcium concentration can be adjusted to be not less than ImmoLZL by combining sodium citrate within the range of 0.2 to 0.5 mEqZL with the value of 1.5 mEqZL or less.
- Example 2 Adjustment of ionized calcium concentration by increasing calcium concentration in analysis solution
- the calcium concentration in the dialysate is fixed at a constant concentration (3. OmEqZL) that is generally widely used, and citrate as a pH adjuster used at that time is used. It is an example of adjusting the ionization power lucum concentration in the dialysate by adjusting the sodium taenate content.
- the ionized calcium concentration in the dialysate can also be adjusted by increasing the calcium concentration in the dialysate.
- the electrolyte concentration was the same as that in the dialysate, except that the calcium concentration was changed to 3.5 mEqZL.
- the dialysate was prepared by
- the ionic calcium concentration and pH value of the dialysate after the preparation were measured with a blood electrolyte measurement device (two types: i—STAT and ABL).
- i—STAT the ionized calcium concentration was 1.15 mmoL / L.
- the pH was 7.53.
- ABL the ionized calcium concentration was 1.26 mmoLZL, and the pH was 7.46.
- the concentration of ionic calcium in the dialysate can be adjusted by increasing the calcium concentration in the dialysate.
- Example 3 Review of ionized calcium (Ca ⁇ ) concentration in clinical trials and trials
- the blood ionized calcium concentration is the reference value in dialysis patients who have been dialyzed with the dialysate of the present invention. 2. 05-2. Values around 60 mEqZL (non-patent It is understood that Reference 1) is secured.
- the present invention provides a preparation for dialysis that serves as a dialysis solution in which a decrease in ionic calcium concentration in the dialysis solution is prevented.
- the preparation A for bicarbonate dialysis preparation provided by the present invention, after preparing the dialysis solution, in particular so that the ionic calcium concentration is not less than ImmoLZL. It is adjusted by combining the content of sodium acid, and has the advantage that a stable bicarbonate dialysis solution can be supplied.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- External Artificial Organs (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006550896A JPWO2006073164A1 (ja) | 2005-01-07 | 2006-01-06 | 透析用製剤 |
US11/794,824 US20090294360A1 (en) | 2005-01-07 | 2006-01-06 | Dialysis preparation |
EP06711450A EP1834652A4 (en) | 2005-01-07 | 2006-01-06 | PREPARATION FOR DIALYSIS |
US14/218,427 US20140197106A1 (en) | 2005-01-07 | 2014-03-18 | Dialysis preparation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005002781 | 2005-01-07 | ||
JP2005-002781 | 2005-01-07 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/794,824 A-371-Of-International US20090294360A1 (en) | 2005-01-07 | 2006-01-06 | Dialysis preparation |
US14/218,427 Continuation US20140197106A1 (en) | 2005-01-07 | 2014-03-18 | Dialysis preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006073164A1 true WO2006073164A1 (ja) | 2006-07-13 |
Family
ID=36647640
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/300051 WO2006073164A1 (ja) | 2005-01-07 | 2006-01-06 | 透析用製剤 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20090294360A1 (ja) |
EP (1) | EP1834652A4 (ja) |
JP (3) | JPWO2006073164A1 (ja) |
CN (2) | CN101123987A (ja) |
WO (1) | WO2006073164A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008072591A1 (ja) * | 2006-12-12 | 2008-06-19 | Ajinomoto Co., Inc. | 鉄代謝改善剤 |
WO2008114679A1 (ja) * | 2007-03-14 | 2008-09-25 | Ajinomoto Co., Inc. | 骨代謝改善剤 |
JP2016503768A (ja) * | 2012-12-18 | 2016-02-08 | ガンブロ・ルンディア・エービーGambro Lundia Ab | 透析組成物 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10993961B2 (en) | 2010-06-23 | 2021-05-04 | Gambro Lundia Ab | Dialysis precursor composition |
ES2677603T3 (es) | 2010-06-23 | 2018-08-03 | Gambro Lundia Ab | Composición precursora de diálisis |
US9616161B2 (en) | 2011-06-20 | 2017-04-11 | Gambro Lundia Ab | Dialysis precursor composition |
EP2720700B1 (en) | 2011-06-20 | 2016-06-01 | Gambro Lundia AB | Dialysis precursor composition |
WO2013092283A1 (en) | 2011-12-21 | 2013-06-27 | Gambro Lundia Ab | Dialysis precursor composition |
CA2855890C (en) | 2011-12-21 | 2019-08-27 | Gambro Lundia Ab | Dialysis precursor composition |
SE536913C2 (sv) | 2012-03-08 | 2014-10-28 | Gambro Lundia Ab | Komposition för dialys |
JP5376480B1 (ja) * | 2012-10-10 | 2013-12-25 | 富田製薬株式会社 | 酢酸及び酢酸塩を含む透析用a剤、及びそれを用いた2剤型透析用剤 |
US10342824B2 (en) | 2017-07-17 | 2019-07-09 | Dr. Marlowe's Weight Loss Institute, P.L.L.C. | Supplement for treating side effects of medications which cause metabolic acidosis |
CN109091499A (zh) * | 2018-08-31 | 2018-12-28 | 山东威高药业股份有限公司 | 一种血液透析浓缩物a粉的制备工艺 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1087478A (ja) * | 1996-09-13 | 1998-04-07 | Tomita Seiyaku Kk | 重炭酸固形透析用剤 |
JP2002282353A (ja) * | 2002-03-08 | 2002-10-02 | Tomita Pharmaceutical Co Ltd | 重炭酸固形透析用剤 |
JP2003104869A (ja) * | 2001-09-28 | 2003-04-09 | Shimizu Pharmaceutical Co Ltd | 透析用剤およびその製造方法 |
JP2003339853A (ja) * | 2002-05-27 | 2003-12-02 | Shimizu Pharmaceutical Co Ltd | 安定な透析用剤 |
JP2004121822A (ja) * | 2002-08-01 | 2004-04-22 | Shimizu Pharmaceutical Co Ltd | 固形透析用剤およびその製造方法 |
JP2005126420A (ja) * | 2003-09-30 | 2005-05-19 | Fuso Pharmaceutical Industries Ltd | 炭酸水素イオン含有薬液 |
JP2005206572A (ja) * | 2003-12-26 | 2005-08-04 | Manac Inc | 一剤型重炭酸透析用固形剤及びその製造方法 |
JP2005239618A (ja) * | 2004-02-26 | 2005-09-08 | Ajinomoto Co Inc | 粉末透析製剤の製造方法 |
WO2005094918A1 (ja) * | 2004-03-30 | 2005-10-13 | Nipro Corporation | 透析用固形製剤 |
JP2005330241A (ja) * | 2004-05-21 | 2005-12-02 | Ajinomoto Co Inc | 固形透析用剤の製造方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5252213A (en) * | 1989-06-20 | 1993-10-12 | University Of Washington | Dry dialysate composition |
EP1218039B1 (en) * | 1999-09-22 | 2009-02-18 | Advanced Renal Technologies | Use of high citrate dialysate |
-
2006
- 2006-01-06 CN CNA2006800054842A patent/CN101123987A/zh active Pending
- 2006-01-06 EP EP06711450A patent/EP1834652A4/en not_active Ceased
- 2006-01-06 JP JP2006550896A patent/JPWO2006073164A1/ja active Pending
- 2006-01-06 CN CN2011104111404A patent/CN102512361A/zh active Pending
- 2006-01-06 WO PCT/JP2006/300051 patent/WO2006073164A1/ja active Application Filing
- 2006-01-06 US US11/794,824 patent/US20090294360A1/en not_active Abandoned
-
2012
- 2012-02-03 JP JP2012021839A patent/JP5840017B2/ja active Active
-
2014
- 2014-03-18 US US14/218,427 patent/US20140197106A1/en not_active Abandoned
- 2014-08-29 JP JP2014174832A patent/JP2014218529A/ja active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1087478A (ja) * | 1996-09-13 | 1998-04-07 | Tomita Seiyaku Kk | 重炭酸固形透析用剤 |
JP2003104869A (ja) * | 2001-09-28 | 2003-04-09 | Shimizu Pharmaceutical Co Ltd | 透析用剤およびその製造方法 |
JP2002282353A (ja) * | 2002-03-08 | 2002-10-02 | Tomita Pharmaceutical Co Ltd | 重炭酸固形透析用剤 |
JP2003339853A (ja) * | 2002-05-27 | 2003-12-02 | Shimizu Pharmaceutical Co Ltd | 安定な透析用剤 |
JP2004121822A (ja) * | 2002-08-01 | 2004-04-22 | Shimizu Pharmaceutical Co Ltd | 固形透析用剤およびその製造方法 |
JP2005126420A (ja) * | 2003-09-30 | 2005-05-19 | Fuso Pharmaceutical Industries Ltd | 炭酸水素イオン含有薬液 |
JP2005206572A (ja) * | 2003-12-26 | 2005-08-04 | Manac Inc | 一剤型重炭酸透析用固形剤及びその製造方法 |
JP2005239618A (ja) * | 2004-02-26 | 2005-09-08 | Ajinomoto Co Inc | 粉末透析製剤の製造方法 |
WO2005094918A1 (ja) * | 2004-03-30 | 2005-10-13 | Nipro Corporation | 透析用固形製剤 |
JP2005330241A (ja) * | 2004-05-21 | 2005-12-02 | Ajinomoto Co Inc | 固形透析用剤の製造方法 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008072591A1 (ja) * | 2006-12-12 | 2008-06-19 | Ajinomoto Co., Inc. | 鉄代謝改善剤 |
KR101467957B1 (ko) * | 2006-12-12 | 2014-12-02 | 아지노모토 가부시키가이샤 | 철 대사 개선제 |
CN105380936A (zh) * | 2006-12-12 | 2016-03-09 | 味之素株式会社 | 铁代谢改善剂 |
WO2008114679A1 (ja) * | 2007-03-14 | 2008-09-25 | Ajinomoto Co., Inc. | 骨代謝改善剤 |
US8715213B2 (en) | 2007-03-14 | 2014-05-06 | Ajinomoto Co., Inc. | Bone metabolism improving agent |
KR101461436B1 (ko) | 2007-03-14 | 2014-11-13 | 아지노모토 가부시키가이샤 | 골 대사 개선제 |
JP5667762B2 (ja) * | 2007-03-14 | 2015-02-12 | エイワイファーマ株式会社 | 骨代謝改善剤 |
JP2016503768A (ja) * | 2012-12-18 | 2016-02-08 | ガンブロ・ルンディア・エービーGambro Lundia Ab | 透析組成物 |
Also Published As
Publication number | Publication date |
---|---|
EP1834652A1 (en) | 2007-09-19 |
US20090294360A1 (en) | 2009-12-03 |
US20140197106A1 (en) | 2014-07-17 |
EP1834652A4 (en) | 2010-01-06 |
JP2014218529A (ja) | 2014-11-20 |
CN101123987A (zh) | 2008-02-13 |
JPWO2006073164A1 (ja) | 2008-06-12 |
CN102512361A (zh) | 2012-06-27 |
JP5840017B2 (ja) | 2016-01-06 |
JP2012131801A (ja) | 2012-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006073164A1 (ja) | 透析用製剤 | |
TWI583378B (zh) | 透析酸前驅物組成物、其用途、以及提供透析酸濃縮物溶液之方法 | |
JP5204359B2 (ja) | 透析用剤およびその製造方法 | |
TWI419683B (zh) | 骨代謝改善劑 | |
JP5975962B2 (ja) | 透析用緩衝化組成物 | |
JP5752791B2 (ja) | 透析酸前駆組成物 | |
Schmitt et al. | Solutions for peritoneal dialysis in children: recommendations by the European Pediatric Dialysis Working Group | |
CN1863539A (zh) | 透析用缓冲的组合物 | |
WO2010112570A1 (en) | Dialysis solution | |
WO2010112547A1 (en) | Dialysis precursor composition | |
JP2003339853A (ja) | 安定な透析用剤 | |
JP6425661B2 (ja) | 透析組成物 | |
CN102573828B (zh) | 通过施用肌酸化合物的透析患者中的细胞保护 | |
JP3867174B2 (ja) | 血液透析製剤 | |
JP5371278B2 (ja) | 透析用剤およびその製造方法 | |
JP5258448B2 (ja) | 透析用製剤 | |
JP2008119509A (ja) | 腹膜透析液調製用溶液セット | |
JP6985937B2 (ja) | 有機リン酸エステルを含有する透析液または置換液 | |
Leblanc | The acid-base effects of acute hemodialysis | |
TWI373339B (en) | Pharmaceutical composition for use in hemofiltration or hemodialysis | |
BG1190U1 (bg) | Концентрати за хемодиализа |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006550896 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006711450 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200680005484.2 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2006711450 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11794824 Country of ref document: US |